- Home
- GORO vs SGMT Comparison
GORO vs SGMT Comparison
Compare GORO & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GORO | SGMT |
|---|---|---|
| Founded | 1998 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.5M | 169.4M |
| IPO Year | 2011 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GORO | SGMT |
|---|---|---|
| Price | $2.83 | $11.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $1.63 | ★ $26.13 |
| AVG Volume (30 Days) | ★ 1.8M | 1.2M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | $25.99 | N/A |
| Revenue Next Year | $5.78 | N/A |
| P/E Ratio | $70.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.44 | $4.50 |
| 52 Week High | $4.00 | $10.61 |
Technical Indicators
Market Signals| Indicator | GORO | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 66.13 | 74.08 |
| Support Level | $0.84 | $6.16 |
| Resistance Level | $4.00 | N/A |
| Average True Range (ATR) | 0.21 | 0.66 |
| MACD | 0.03 | 0.25 |
| Stochastic Oscillator | 78.45 | 94.31 |
Price Performance
Historical ComparisonAbout GORO Gold Resource Corporation
Goldgroup Mining Inc is focused on the acquisition, exploration and development of stage gold-bearing mineral properties in the Americas. The Companies current gold production and exploration and development related activities are conducted in Mexico. It property portfolio include Cerro Prieto project in Sonora and Pinos Project.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.